Laverock Therapeutics Secures Over €23.3M to Advance Programmable Gene Control Platform for Precision Therapies

The round was led by Calculus Capital, with continued support from Eli Lilly and Company, Mercia Ventures, Eos Advisory, and Maven Capital Partners, along with new investor Norcliffe Capital.

Pioneering Disease-Responsive Gene Control

Founded in 2021, Laverock Therapeutics is developing a novel gene control platform based on recoded microRNAs (miRNAs). This approach enables programmable, tunable, and multiplex gene silencing, allowing the creation of disease-responsive advanced therapies that offer superior precision and safety.

The company is advancing its internal pipeline in oncology and genetic medicine, while also preparing to license its platform to partners looking to enhance their own therapeutic development programs.

“This new funding enables us to continue advancing our platform and therapeutic programs, while also pursuing key collaborations,” said David Venables, CEO of Laverock Therapeutics. “We’re grateful to our investors for their ongoing support and belief in our mission.”

Demonstrated Progress in Cancer Models

Laverock has recently reached key development milestones, generating positive functional data in both its T-cell and macrophage programs. These data showed enhanced tumour control in solid and haematological cancer models, validating the platform’s potential in immuno-oncology.

The startup’s innovative technology leverages natural regulatory mechanisms within the cell to achieve highly controlled gene expression, paving the way for a next generation of safer, more effective advanced therapies.

Investor Confidence and Strategic Vision

“Laverock is pioneering a new era of programmable therapies,” said Elizabeth Klein, Investment Director at Calculus Capital. “We’re excited to support their transition from platform validation to product development and partnership expansion.”

The company also unveiled a new corporate identity and website, reflecting its growth trajectory and increasing emphasis on partnering and outlicensing its gene control technologies.

With this new investment, Laverock is well-positioned to become a key player in precision medicine, offering a robust alternative to traditional gene editing approaches through its unique RNA-based platform.